Back to articles

Calcium channel blocker better than thiazide for CKD with ACE inhibitor


A secondary, prespecified analysis of the ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial showed that combination therapy with benazepril, an ACE inhibitor, and amlodipine, a calcium channel blocker, reduced the progression to chronic kidney disease (CKD) compared with benazepril and hydrochlorothiazide (3.7% vs. 2.0%, respectively).